Pulmonary vascular disorders in portal hypertension

European Respiratory Journal

Volumn 11, Issue 5, 1998, Pages 1153-1166

  Herve P ^a,c   Lebrec, D ^b   Brenot, F ^a   Simonneau, G ^a   Humbert, M ^a   Sitbon, O ^a   Duroux, P ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b BEAUJON HOSPITAL   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

Author keywords

Cirrhosis; Hepatopulmonary syndrome; Hypoxaemia; Portal hypertension; Pulmonary hypertension

Indexed keywords

CLINICAL FEATURE; HEPATOPULMONARY SYNDROME; HISTOPATHOLOGY; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LUNG HEMODYNAMICS; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW;

HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; PULMONARY CIRCULATION; SYNDROME; VASCULAR DISEASES;

EID: 0031844681     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.98.11051153     Document Type: Review

References (88)

1. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991; 100: 520-528.
2. Kowalski HJ, Abelmann WH. The cardiac output in Laennec cirrhosis. J Clin Invest 1953; 32: 1025-1033.
3. Kontos HA, Shapiro W, Mauck HP, Patterson JL. General and regional circulatory alterations in cirrhosis of the liver. Am J Med 1964; 37: 526-535.
4. Murray JF, Dawson AM, Sherlock S. Circulatory changes in chronic liver disease. Am J Med 1958; 24: 258-267.
5. Campillo B, Bories PN, Benvenutti C, Dupeyron C. Serum and urinary nitrate levels in liver cirrhosis: endotoxinemia, renal function and hyperdynamic circulation. J Hepatol 1996; 24: 707-714.
6. Campillo B, Chabrier PE, Pelle G, et al. Inhibition of nitric oxide synthesis in the forearm arterial bed of patients with advanced cirrhosis. Hepatology 1995; 22: 1423-1429.
7. Rodriguez-Roisin R, Roca J, Agusti AGN, Mastai R, Wagner PD, Bosch J. Gas exchange and pulmonary vascular reactivity in patients with liver cirrhosis. Am Rev Respir Dis 1987; 135: 1085-1092.
8. Daoud FS, Reeves JT, Scaeffer JW. Failure of hypoxic vasoconstriction in patients with liver cirrhosis. J Clin Invest 1971; 51: 1076-1080.
9. Naeije R, Hallemans R, Mols P, Melot C. Hypoxic pulmonary vasoconstriction in liver cirrhosis. Chest 1981; 80: 570-574.
10. Naeije R, Melot C, Hallemans R, Mols P, Lejeune P. Pulmonary hemodynamics in liver cirrhosis. Semin Respir Med 1985; 7: 164-170.
11. Melot C, Naeije R, Dechamps P, Hallemans R, Lejeune P. Pulmonary and extrapulmonary contributors to hypoxemia in liver cirrhosis. Am Rev Respir Dis 1989; 139: 632-640.
12. Lunzer MR, Newman SP, Bernard AG, Maughani KK, Sherlock SP, Ginsburg J. Impaired cardiovascular responsiveness in liver disease. Lancet 1975; ii: 382-385.
13. Panos RJ, Backer SK. Mediators, cytokines, and growth factors in liver-lung interactions. Clin Chest Med 1996; 17: 151-169.
14. Sogni P, Moreau R, Gadano A, Lebrec D. The role of nitric oxide in the hyperdynamic circulatory syndrome associated with portal hypertension. J Hepatol 1995; 23: 218-224.
15. Lundberg JON, Weitzberg E, Lundberg JM, Alving K. Nitric oxide in exhaled air. Eur Respir J 1996; 9: 2671-2680.
16. Matsumoto A, Ogura K, Kakoki M, et al. Increased nitric oxide in the exhaled air of patients with decompensated liver cirrhosis. Ann Intern Med 1995; 123: 110-113.
17. Sogni P, Gamier P, Moreau R, Dall'Ava-Santucci J, Dinh-Xuan AT, Lebrec D. Endogenous pulmonary nitric oxide production measured from exhaled air is increased in patients with severe cirrhosis. J Hepatol 1995; 23: 471-474.
18. Cremona G, Higenbottam TW, Alexander G, et at. Elevated nitric oxide in patients with hepatopulmonary syndrome. Eur Respir J 1995; 8: 1883-1885.
19. Hori N, Okanoue T, Kashima K, et al. Endogenous nitric oxide production is augmented as the severity advances in patients with liver cirrhosis. Clin Exp Pharmacol Physiol 1996; 23: 30-35.
20. Rolla G, Brussino L, Colagrande P, et al. Exhaled nitricoxide and oxygenation abnormalities in hepatic cirrhosis. Hepatology 1997; 26: 842-847.
21. Albillos A, Rossi I, Martinez MV, Abreu L, Barrios C, Escartin P. Enhanced endothelium-dependent vasodilation in patients with cirrhosis. Am J Physiol 1995; 268: G459-G464.
22. Calver A, Harris A, Maxwell JD, Vallance P. Effect of local inhibition of nitric oxide synthesis on forearm arterial bed of patients with alcoholic cirrhosis. Clin Sci 1994; 86: 203-208.
23. Vallance P, Moncada S. Hyperdynamic circulation in liver cirrhosis: a role for nitric oxide? Lancet 1991; 337: 776-779.
24. Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxinemia. Hepatolagy 1993; 18: 1139-1143.
25. Le Moine O, Soupison T, Sogni P, et al. Plasma endotoxin and tumor necrosis tactor-α in the hyperkinetic state of cirrhosis. J Hepatol 1995; 22: 391-395.
26. Laffy G, Foschi M, Simoni A. el al. Increased production of nitric oxide by neutrophils and monocytes from patients with ascites and hyperdynamic circulation. Hepatology 1995; 22: 1666-1673.
27. Chang SW, Ohara N. Pulmonary circulatory dysfunction in rats with biliary cirrhosis: an animal model of the hepatopulmonary syndrome. Am Rev Respir Dis 1992; 145: 796-805.
28. Niederberger M, Martin PY, Ginès P, et al. Normalization of nitric oxide production corrects arterial vasodilatation and hyperdynamic circulation in cirrhotic rats. Gastroenterology 1995; 109: 1624-1630.
29. Pilette C, Kirstetter P, Sogni P, Moreau R, Lebrec D. Dose-dependent effects of a nitric oxide biosynthesis inhibitor on hyperdynamic circulation in two models of portal hypertension in conscious rats. J Gastroenterol Hepatol 1996; 11: 1-6.
30. Chabot F, Mestiri H, Dall'Ava-Santucci J, Lockhart A, Dinh-Xuan AT. Role of NO in the pulmonary hyporeactivity to phenylephrine in experimental biliary cirrhosis. Ear Respir J 1996; 9: 560-564.
31. Fallon MB, Abrams GA, Ifou Z, et al. The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome. Gastroenterology 1997; 113: 606-614.
32. Weigert AL, Martin PY, Niederberger M, et al. Endothelium-dependent vascular hyporesponsiveness without detection of nitric oxide synthase induction in aortas of cirrhotic rats. Hepatology 1995; 22: 1856-1862.
33. Morales-Ruiz M, Jimenez W, Pierez-Sala D, et al. Increased nitric oxide synthase expression in arterial vessels of cirrhotic rats with ascites. Hepatology 1996; 24: 1481-1484.
34. El-Newihi HM, Kanji VK, Mihas AA. Activity of gastric mucosal nitric oxide synthase in portal hypertensive gastropathy. Am J Gastroenterology 1996; 91: 535-538.
35. Rich S, Dantzker DR, Ayres SM. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107: 216-223.
36. Castro M, Krowka MJ, Schroeder DR, et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplantation. Mayo Clin Proc 1996; 71: 543-551.
37. Mandell SM, Groves BM. Pulmonary hypertension in liver disease. Clin Chest Med 1996; 17: 17-33.
38. McDonnel PJ, Toye PA, Hutchins GM. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 1983; 127: 437-441.
39. Tamara P, Garcia-Valdecasas JC, Beltran J, et al. Moderate primary pulmonary hypertension in patients undergoing liver transplantation. Anaesth Analg 1996; 83: 675-680.
40. Rubin LJ. Primary pulmonary hypertension. ACCP consensus statement. Chest 1993; 104: 236-250.
41. Brenot F, Simonneau G. Risks factor for primary pulmonary hypertension. In: Rubin LJ, Rich S, eds. Primary Pulmonary Hypertension. Lung Biology in Health and Diseases, Vol. 99. New York, Marcel Dekker, 1997; pp. 131-149.
42. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609-616.
43. Nichols WC, Koller DL, Slovis B, et al. Localization of the gene for familial primary pulmonary hypertension. Nat Genet 1997; 15: 277-280.
44. Osterud B, Bajaj MS, Bajaj SP. Sites of tissue factor pathway inhibitor and tissue factor expression under physiologic and pathologic conditions. Thomb Haemost 1995; 73: 873-875.
45. Brown SL, Lundgren CH, Nordt T, Fujii S. Stimulation of migration of human aortic smooth muscle cell by vitronectin: implications for atherosclerosis. Cardiovasc Res 1994; 28: 1815-1820.
46. Rabinovitch M. Mechanisms of pulmonary hypertension in chronic high flow states. In: Weir EK, Reeves JT, eds. Pulmonary Vascular Physiology and Pathophysiology. Lung Biology in Health and Diseases, Vol. 38. New York, Marcel Dekker, 1989; pp. 469-511.
47. Hervé P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in patients with primary pulmonary hypertension. Am J Med 1995; 99: 249-254.
48. Hervé P, Drouet L, Dosquet C, Simonneau G, Launay JM, Duroux P. Primary pulmonary hypertension in a patient with a familial storage pool disease: role of serotonin. Am J Med 1990; 89: 117-120.
49. Humbert M, Monti G, Brenot F, et al. Increased serum interleukin-1 and interleukin-6 concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 151: 1628-1631.
50. Fanburg B, Lee SL. A new role for an old molecule: serotonin. Am J Physiol 1997; 272: L795-L806.
51. Beaudry P, Hadengue A, Callebert J, et al. Blood and plasma 5-hydroxytryptamine levels in patients with cirrhosis. Hepatology 1994; 20: 800-803.
52. Ashmore RC, Rodman DM, Sato K, et al. Paradoxical constriction to platelets by arteries from rats with pulmonary hypertension. Am J Physiol 1991; 260: H1929-H1934.
53. Sato K, Webb S, Tucker A, et al. Factors influencing the idiopathic development of pulmonary hypertension in the fawn hooded rat. Am Rev Respir Dis 1992; 145: 793-797.
54. Voelkel NF, Tuder RM, Weir EK. Pathophysiology of primary pulmonary hypertension: from physiology to molecular mechanisms. In: Rubin LJ, Rich S, eds. Primary Pulmonary Hypertension. Lung Biology in Health and Diseases, Vol. 99. New York, Marcel Dekker, 1997; pp. 83-129.
55. 165 in patients with ischemic limb. Lancet 1996; 348: 370-374.
56. Groves BM, Brundage BH, Elliot CG, et al. Pulmonary hypertension associated with hepatic cirrhosis. In: Fishman AP, ed. The Pulmonary Circulation: Normal and Abnormal. Philadelphia, PA, University of Pennsylvania Press, 1990; pp. 359-369.
57. Kneussl MP, Lang IM, Brenot FP. Medical management of primary pulmonary hypertension. Eur Respir J 1996; 9: 2401-2409.
58. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
59. Kuo PC, Plotkin JS, Howell CD, Battlett ST, Rubin LJ. Continuous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997; 63: 604-606.
60. Castro M, Krowka MJ. Hepatopulmonary syndrome: a pulmonary vascular complication of liver disease. Clin Chest Med 1996; 17: 35-48.
61. Berthelot P, Walker JG, Sherlock S, Reid L. Arterial changes in the lungs in cirrhosis of the liver: lung spider naevi. N Engl J Med 1966; 274: 291-298.
62. Krowka MJ, Dickson ER, Cortese DA. Hepatopulmonary syndrome: clinical observations and lack of therapeutic response to somatostatine analogue. Chest 1993; 104: 515-521.
63. Agusti AGN, Roca J, Rodriguez-Roisin R. Mechanisms of gas exchange impairment in patients with liver cirrhosis. Clin Chest Med 1996; 17: 49-66.
64. Rodriguez-Roisin R, Agusti AGN, Roca J. The hepatopulmonary syndrome: new name, old complexities. Thorax 1992; 47: 897-902.
65. Crawford ABH, Regnis J, Laks L, Donnelly P, Engel LA, Young IH. Pulmonary vascular dilatation and diffusiondependent impairment of gas exchange in liver cirrhosis. Eur Respir J 1995; 8: 1913-1919.
66. Wagner PD. Impairment of gas exchange in cirrhosis. Eur Respir J 1995; 8: 1993-1995.
67. Vachiery F, Moreau R, Hadengue A, et al. Hypoxemia in patients with cirrhosis: relationship with liver failure and hemodynamic alterations. J Hepatol 1997; 27: 492-495.
68. Rolla G, Bucca C, Brussino L. Methylene blue in the hepatopulmonary syndrome. N Engl J Med 1994; 331: 1098.
69. Fallen MB, Abrams GA, McGrath JW, Hou Z, Luo B. Common bile duct ligation in the rat: a model of intrapulmonary vasodilatation and hepatopulmonary syndrome. Am J Physiot 1997; 272: G779-G784.
70. Luo B, Abrams GA, Fallon MB. Endothelin-1: a potential mediator of intrapulmonary vasodilatation in a rat model of hepatopulmonary syndrome. Hepatology 1997; 26: A390.
71. Schraufnagel DE, Malik R, Goel V, Ohara N, Chang SW. Lung capillary changes in hepatic cirrhosis in rats. Am J Physiol 1997; 272: L139-L147.
72. Srivastava D, Preminger T, Lock JE, et al. Hepatic venous blood and the development of pulmonary arteriovenous malformations in congenital heart disease. Circulation 1995; 92: 1217-1222.
73. Shah MJ, Rychick J, Fogel MA, Murphy JD, Jacobs ML. Pulmonary arteriovenous malformations after superior cavopulmonary connection: resolution after inclusion of hepatic veins in the pulmonary circulation. Ann Thorac Sura 1997; 63: 960-963.
74. Graham K, Sonheimer H, Schafter M. Resolution of cavopulmonary shunt-associated pulmonary arteriovenous malformation after heart transplantation. J Heart Lung Transplant 1997; 16: 1271-1274.
75. Lamour JM, Hsu DT, Kichuk MR, et al. Regression of pulmonary arteriovenous malformations following heart transplantation. J Heart Lung Transplant 1997; 16: A71.
76. Lange PA, Stoller JK. The hepatopulmonary syndrome. Ann Intern Med 1995; 122: 521-529.
77. Krowka MJ, Cortese DA. Pulmonary aspect of liver disease and liver transplantation. Clin Chest Med 1989; 10: 593-616.
78. Vedrinne JM, Duperret S, Bizollon T, et al. Comparison of transesophageal and transthoracic contrast echocardiography for detection of an intapulmonary shunt in liver disease. Chest 1997; 111: 1236-1240.
79. Abrams GA, Jaffe CC, Hoffer PB, Binder HJ. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. Gastroenterology 1995; 109: 1283-1288.
80. Krowka MJ, Porayko MK, Plevak DJ, et al. Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: case reports and literature review. Mayo Clin Proc 1997; 72: 44-53.
81. Poterucha JJ, Krowka MJ, Dickson ER, Cortese DA, Stanson AW, Krom RAF. Failure of hepatopulmonary syndrome to resolve after liver transplantation and successful treatment with embolotherapy. Hepatology 1995; 21: 96-100.
82. Cadranel JL, Milleron BJ, Cadranel JF, et al. Severe hypoxemia-associated intrapulmonary shunt in a patient with chronic liver disease: improvement after medical treatment. Am Rev Respir Dis 1992; 146: 526-527.
83. Battaglia SE, Pretto JJ, Irving LB, Jones RM, Angus PW. Resolution of gas exchange abnormalities and intrapulmonary shunting following liver transplantation. Hepatology 1997; 25: 1228-1232.
84. Krowka MJ. Hepatopulmonay syndrome versus portopulmonary hypertension: distinctions and dilemmas. Hepatology 1997; 25: 1282-1284.
85. Raffy O, Sleiman C, Vachiery F, el al. Refractory hypoxemia during liver cirrhosis: hepatopulmonary syndrome or "primary pulmonary hypertension". Am J Respir Crit Care Med 1996; 153: 1169-1171.
86. Dawson A, Elias DJ, Rubenson D, er al. Pulmonary hypertension developing after aglucerase therapy in two patients with type I Gaucher disease complicated by the hepatopulmonary syndrome. Ann Intern Med 1996; 125: 901-904.
87. Tasaka S, Kanazawa M, Nakamura H, et al. An autopsied case of primary pulmonary hypertension complicated by hepatopulmonary syndrome. Nippon Kyobu Shikkan Gakkai Zasshi 1995; 33: 90-94.
88. Mandall MS, Krowka MJ. Formation of a national database on pulmonary hypertension and hepatopulmonary syndrome in chronic liver disease. Anesthesiology 1997; 87: 450-451.